Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UV 1

Next Previous
Drug Profile

UV 1

Alternative Names: UV-1; UV1 synthetic peptide vaccine; UV1 vaccine

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norwegian Radium Hospital; Ultimovacs AS
  • Developer Oslo University Hospital; Ultimovacs AS
  • Class Cancer vaccines; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 15 Nov 2019 Efficacy data from a phase I/II trial in Prostate cancer (Metastatic disease, Newly diagnosed) released by Ultimovacs
  • 09 Nov 2019 Efficacy and adverse events data from a phase I/IIa trial in Non-small cell lung cancer (Late-stage disease, Second line therapy or greater) released by Ultimovacs
  • 21 Aug 2019 Ultimovacs plans a phase II trial in Malignant melanoma (Combination therapy) in USA, European Union and Australia in the first quarter of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top